China
Africa
Explore chapters and articles related to this topic
Breast cancer
Published in Peter Hoskin, Peter Ostler, Clinical Oncology, 2020
Bisphosphonates such as zoledronic acid and ibandronic acid have a role in those with skeletal metastatic disease. Denosumab (a humanized monoclonal antibody to RANKL) is also an active agent. Regular administration of such therapies may reduce: Risk of bone painRisk of hypercalcaemiaRisk of pathological fractureNeed for palliative radiotherapyTumour-related complications
I
Published in Caroline Ashley, Aileen Dunleavy, John Cunningham, The Renal Drug Handbook, 2018
Caroline Ashley, Aileen Dunleavy, John Cunningham
After initial systemic exposure, ibandronic acid rapidly binds to bone or is excreted into urine. There is no evidence that ibandronic acid is metabolised in animals or humans. The absorbed fraction of ibandronic acid is removed from the circulation via bone absorption (estimated to be 40–50% in postmenopausal women) and the remainder is eliminated unchanged by the kidney. The unabsorbed fraction of ibandronic acid is eliminated unchanged in the faeces. Renal clearance accounts for 50–60% of total clearance and is related to creatinine clearance. The difference between the apparent total and renal clearances is considered to reflect the uptake by bone.
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States
Published in Current Medical Research and Opinion, 2019
David Henry, Roger von Moos, Jean-Jacques Body, Alex Rider, Jonathan De Courcy, Debajyoti Bhowmik, Francesca Gatta, Guy Hechmati, Yi Qian
Of the 337 patients treated with bone-targeted agents, the majority received zoledronic acid (n = 161, 48%) or denosumab (n = 140, 42%), and less frequently pamidronic acid, clodronic acid or ibandronic acid (Figure 1). For those treated with denosumab, 99% received the treatment every 4 weeks. For those treated with zoledronic acid, 83% received the treatment every 4 weeks and 14% received the treatment every 3 weeks. The median number of doses of denosumab and zoledronic acid administered was four. The median length of treatment for denosumab and zoledronic acid was 3 months.